List of Excipients in Branded Drug CARBOPLATIN

Generic Drugs Containing CARBOPLATIN

Company	Ingredient	NDC	Excipient
Teva Parenteral Medicines Inc	carboplatin	0703-4244	MANNITOL
Teva Parenteral Medicines Inc	carboplatin	0703-4244	WATER
Teva Parenteral Medicines Inc	carboplatin	0703-4248	MANNITOL
Teva Parenteral Medicines Inc	carboplatin	0703-4248	WATER
Accord Healthcare Inc	carboplatin	16729-295	WATER
Sun Pharmaceutical Industries Inc	carboplatin	47335-150	WATER

What are the Most Frequently-Used Excipients in CARBOPLATIN?

# Of NDCs	Excipient
5	MANNITOL
18	WATER

Carboplatin Excipient Strategy, Patent Landscape, and Commercial Opportunities

Last updated: September 5, 2026

Carboplatin is an off-patent platinum chemotherapy supplied primarily as a sterile aqueous intravenous solution. The active ingredient offers limited composition-of-matter or exclusivity value. Commercial differentiation depends on excipient control, stability, container compatibility, ready-to-administer presentation, supply reliability, and oncology workflow economics.

The strongest near-term opportunities are preservative-free ready-to-use infusion bags, concentration-standardized products, extended in-use stability, low-volume presentations, and packaging systems that reduce compounding steps. The main technical constraint is carboplatin’s compatibility with aluminum-containing administration components and the need to preserve potency during storage and dilution.

What is the FDA regulatory status of carboplatin?

Carboplatin is FDA-approved for intravenous treatment of advanced ovarian carcinoma and is used widely in other oncology regimens, including lung, breast, head and neck, and germ-cell cancers. The reference product, Paraplatin, was approved in 1989. Multiple generic carboplatin injection products are approved under abbreviated new drug applications, or ANDAs [1].

Attribute	Carboplatin status
Active ingredient	Carboplatin
Therapeutic class	Platinum antineoplastic
Primary route	Intravenous infusion
Reference product	Paraplatin
Original U.S. approval	1989
Regulatory category	Generic injectable products widely approved
Pediatric exclusivity	No current product-specific exclusivity identified
Orphan exclusivity	No active product-specific orphan exclusivity identified
Biosimilar pathway	Not applicable; carboplatin is a small-molecule drug
Primary commercial forms	Sterile aqueous injection and pharmacy-compounded infusion

Carboplatin is not a biologic, so biosimilar competition does not apply. Competition occurs through ANDA-approved generics, hospital purchasing contracts, group purchasing organizations, and oncology distribution channels.

What excipients are used in carboplatin injection?

The dominant commercial formulation is a preservative-free aqueous solution. U.S. labels commonly identify water for injection and mannitol as inactive ingredients. Some products also use hydrochloric acid or sodium hydroxide for pH adjustment [2,3].

Excipient or component	Function	Commercial relevance
Water for injection	Solvent	Required aqueous vehicle
Mannitol	Tonicity and formulation support	Common in commercial carboplatin injections
Hydrochloric acid	pH adjustment	Process and stability control
Sodium hydroxide	pH adjustment	Process and stability control
5% dextrose injection	Diluent for infusion	Common hospital preparation medium
0.9% sodium chloride injection	Diluent in some institutional protocols	Requires product-specific stability confirmation
Container and closure system	Maintains sterility and chemical quality	Important for extractables, adsorption, and aluminum control

The simplest formulation is usually the strongest regulatory and manufacturing option because it minimizes inactive-ingredient changes and reduces the need for clinical justification. A new excipient system should have a defined purpose, such as extended stability, lower volume, improved cold-chain performance, or ready-to-use administration.

What excipients should be avoided?

Aluminum-containing needles, syringes, and administration sets are a central compatibility concern. Carboplatin labels warn that contact with aluminum can cause particulate formation and loss of potency [2]. The risk affects both primary packaging and secondary administration components.

Potentially problematic formulation choices include:

• Aluminum-containing contact surfaces.
• Reactive metal components in transfer devices.
• Preservatives that are not justified for a cytotoxic injectable.
• Surfactants that increase extractables or create particulate risk.
• Unnecessary buffers that increase ionic complexity.
• Excipients that complicate terminal sterilization or container closure integrity.

A commercial development program should test the complete product-contact system, not only the bulk solution. The assessment should cover vials, stoppers, syringes, transfer spikes, infusion bags, tubing, and closed-system transfer devices.

What formulation patents protect carboplatin products?

The original carboplatin composition-of-matter and early formulation protection have expired. Carboplatin is therefore a mature generic active pharmaceutical ingredient rather than a product with meaningful molecule-level exclusivity.

Protection category	Current commercial significance
Carboplatin molecule	Low; legacy protection expired
Basic aqueous injection	Low; established generic formulation
Mannitol-containing solution	Low unless linked to a narrow new claim
Ready-to-use infusion bag	Potentially moderate if claims cover composition, container, or stability
Low-volume or concentrated presentation	Potentially moderate, subject to clinical and stability requirements
Manufacturing process	Moderate if it materially improves impurity control, yield, or supply reliability
Container and transfer system	Moderate if claims cover aluminum exclusion or integrated administration
Method of use	Low for established generic indications; potentially higher for new combinations or dosing protocols
Digital dosing or workflow platform	Usually outside traditional drug patent value unless integrated with a drug-device system

A sponsor pursuing a new carboplatin product should focus on narrowly drafted formulation, container, process, or combination claims. Broad claims covering carboplatin in water, saline, dextrose, or mannitol are likely to face substantial validity and obviousness challenges because these approaches are well established.

How many patents cover carboplatin?

No material active composition-of-matter patent estate protects carboplatin in the United States. The relevant landscape consists mainly of legacy patents, generic manufacturer process patents, hospital workflow technology, packaging rights, and possible patent filings directed to specialized delivery systems.

The practical freedom-to-operate analysis should search:

1. U.S. patents and published applications assigned to generic injectable manufacturers.
2. Patents covering premixed oncology infusion bags.
3. Container closure and transfer systems designed for hazardous drugs.
4. Nanoparticle, liposomal, implantable, or localized carboplatin delivery.
5. Combination regimens involving carboplatin and newer oncology agents.
6. Manufacturing processes that use specific crystallization, purification, or impurity-control steps.

A patent search should distinguish live claims from expired family members and should not treat a publication alone as an enforceable barrier.

When does carboplatin lose exclusivity?

Carboplatin lost practical U.S. exclusivity years ago. The reference product was approved in 1989, and generic competition has been established for many years. No current reference-product exclusivity period is expected to block ANDA competition.

Exclusivity type	Carboplatin position
New chemical entity exclusivity	Expired
Five-year data exclusivity	Expired
Three-year clinical investigation exclusivity	No current barrier identified
Orphan exclusivity	No current barrier identified
Pediatric exclusivity	No current barrier identified
Patent-based exclusivity	No active molecule-level barrier identified
ANDA entry	Available subject to product-specific FDA requirements

The commercial question is not when carboplatin loses exclusivity. It is whether a differentiated formulation can obtain a separate approval and defendable market position despite a low-cost generic base.

What generic entry risks exist for a new carboplatin formulation?

A new product faces three principal risks: weak differentiation, limited pricing power, and rapid substitution by existing generics.

1. ANDA substitution pressure

A conventional 10 mg/mL vial with water, mannitol, and pH adjustment has little room for premium pricing. Hospitals generally view such products as interchangeable procurement items, subject to FDA-approved labeling, contract terms, and supply availability.

2. 505(b)(2) development burden

A modified product may require a 505(b)(2) application rather than an ANDA if it differs materially in concentration, dosage form, route, formulation, container, or administration method. The sponsor may need comparative stability, extractables and leachables, container compatibility, and clinical or pharmacokinetic support, depending on the change [4].

3. Limited clinical differentiation

Carboplatin’s dosing is commonly calculated using renal function and target exposure, including the Calvert formula. A formulation that does not reduce dosing errors, preparation time, waste, or administration burden may provide little value beyond existing generics.

What commercial opportunities exist for carboplatin excipients?

Ready-to-use infusion bags

Ready-to-use products can reduce pharmacy compounding, hazardous-drug exposure, preparation time, and dosing transcription errors. A product could be offered in standardized concentrations or patient-specific dose ranges.

The main development issues are:

• Long-term stability in the selected infusion bag.
• Compatibility with tubing and transfer devices.
• Low extractables and leachables.
• Particulate control.
• Sterility assurance.
• Protection from light if required by the finished product.
• Defined in-use stability after removal from controlled storage.

A ready-to-use bag is more commercially defensible than a conventional vial, but it carries higher manufacturing and distribution requirements.

Concentrated, low-volume presentations

A higher-concentration presentation could reduce infusion volume and storage footprint. The tradeoff is greater sensitivity to precipitation, dosing errors, local irritation, and administration-device compatibility.

The product should not be positioned solely as "more concentrated." The commercial case must quantify pharmacy labor savings, reduced waste, lower shipping cost, or improved suitability for ambulatory oncology.

Extended-stability formulations

Extended stability after dilution could support centralized pharmacy preparation and regional distribution. The formulation must establish potency, impurity profile, pH, osmolality, particulate limits, sterility, and container closure integrity over the proposed period.

A stability claim is commercially useful only if it changes pharmacy practice. Longer shelf life in the original vial has less value than validated stability in the actual infusion bag and tubing system used by hospitals.

Aluminum-free administration systems

An integrated aluminum-free product platform could combine carboplatin with compatible syringes, spikes, tubing, and transfer components. The value lies in risk reduction and standardized handling rather than in the active ingredient.

This opportunity may support device patents, packaging claims, or bundled contracting. It also requires regulatory review of the drug-device configuration and compatibility data.

Supply-security products

Carboplatin has experienced periods of supply pressure in the U.S. oncology market. A manufacturer with secure platinum raw-material sourcing, redundant fill-finish capacity, and reliable inventory could win hospital contracts even without a novel excipient.

Supply advantages may be reinforced by:

• Dual-source active pharmaceutical ingredient procurement.
• Domestic or geographically diversified sterile manufacturing.
• Multiple vial sizes.
• Prequalified alternative components.
• Buffer inventory for oncology wholesalers.
• Shorter lead times than incumbent suppliers.

How does carboplatin compare with cisplatin and oxaliplatin?

Carboplatin competes clinically with other platinum agents but has different formulation and commercial characteristics.

Attribute	Carboplatin	Cisplatin	Oxaliplatin
Primary formulation	Aqueous IV solution	Aqueous IV solution	Aqueous IV solution or lyophilized presentations depending on market
Key formulation issue	Aluminum compatibility and stability after dilution	Light, chloride, hydration, and compatibility considerations	Stability, dilution medium, and container compatibility
Common commercial position	Generic, price-sensitive	Generic, price-sensitive	Generic with broader colorectal-cancer commercial relevance
Excipient differentiation	Ready-to-use bags, tonicity, stability	Hydration and administration workflow	Reconstitution and infusion convenience
Biosimilar exposure	None	None	None
Premium opportunity	Operational efficiency	Administration and hydration management	Convenience and regimen integration

Carboplatin’s lower nephrotoxicity relative to cisplatin supports continued use in regimens where renal tolerability and outpatient administration matter. Its major commercial weakness is commoditization.

Which companies are challenging carboplatin incumbents?

Competition is primarily among generic injectable manufacturers, specialty oncology suppliers, and hospital-contract vendors. The relevant competitors vary by country and time because supply arrangements, shortages, and product discontinuations change frequently.

A competitive assessment should compare:

• FDA-approved vial strengths.
• Ready-to-use versus concentrate presentations.
• Availability of 50 mg, 150 mg, 450 mg, and 600 mg configurations.
• Contracting position with group purchasing organizations.
• Supply reliability during shortages.
• Product-specific stability information.
• Manufacturing-site redundancy.
• Repackaging and specialty-distribution capabilities.

No biosimilar competitor is relevant because carboplatin is a small molecule. The main threat to a differentiated entrant is generic substitution and hospital tender pricing.

What patent litigation and Paragraph IV risks affect carboplatin?

Carboplatin has no widely recognized current Paragraph IV dispute that creates a broad market-entry barrier for conventional generic injection. Paragraph IV exposure would arise mainly from a new patented formulation, container system, process, or combination product.

For a sponsor launching a differentiated product, the litigation risk is more likely to involve:

• Validity of narrow formulation claims.
• Obviousness based on established aqueous carboplatin formulations.
• Infringement of container or device claims.
• Process claims involving purification or impurity control.
• Patent term and terminal-disclaimer issues.
• Overlap with hospital compounding or premix technology.

A new formulation should be supported by a claim set that ties the excipient system to measurable technical results, such as improved stability, reduced platinum loss, lower particulate formation, or compatibility with a defined non-aluminum administration system.

What is the revenue exposure for carboplatin manufacturers?

Revenue exposure is high for manufacturers that sell only standard injectable carboplatin. The product is vulnerable to:

• Contract repricing.
• Hospital formulary substitution.
• Generic tender competition.
• Active pharmaceutical ingredient shortages.
• Sterile manufacturing interruptions.
• Low switching costs for buyers.
• Limited ability to raise price without a supply event.

A differentiated product can improve revenue quality if it generates service value through ready-to-use delivery, pharmacy labor reduction, or guaranteed supply. The highest-value customers are large oncology networks, centralized health-system pharmacies, ambulatory infusion centers, and specialty distributors.

How strong is the patent estate for a carboplatin excipient strategy?

The patent estate is weak for conventional formulations and potentially moderate for a technically distinct delivery system.

Strategy	Patent strength	Commercial potential
Carboplatin plus water for injection	Low	Low
Carboplatin plus mannitol	Low	Low
Standard 10 mg/mL vial	Low	Low
New concentration with validated stability	Moderate	Moderate
Ready-to-use infusion bag	Moderate	High if workflow benefits are proven
Aluminum-free integrated delivery system	Moderate	Moderate to high
Novel nanoparticle or targeted delivery	Potentially high	High development risk
New manufacturing impurity-control process	Moderate	Moderate
New oncology combination	Variable	Dependent on clinical and patent position

The strongest business case combines a modest formulation change with operational value. A purely excipient-based patent without measurable clinical, stability, or workflow benefit is unlikely to support durable pricing.

Key Takeaways

• Carboplatin is an established generic injectable with no meaningful molecule-level exclusivity.
• Commercial opportunity lies in formulation execution, packaging, supply reliability, and pharmacy workflow.
• Mannitol and water for injection are common formulation components; hydrochloric acid and sodium hydroxide may be used for pH adjustment.
• Aluminum compatibility is a central technical and regulatory issue.
• Ready-to-use infusion bags and standardized concentrations offer the clearest product opportunities.
• A modified formulation may require a 505(b)(2) application rather than an ANDA.
• Conventional carboplatin vials face intense generic substitution and limited pricing power.
• No biosimilar competition applies.
• New patents should focus on measurable stability, container compatibility, manufacturing, or administration advantages.
• The best commercial strategy is a differentiated, supply-secure presentation that reduces pharmacy labor and handling risk.

FAQs

Can carboplatin be formulated with preservatives?

Carboplatin injection is generally supplied as a preservative-free sterile product. Adding a preservative could create toxicology, compatibility, and regulatory burdens that are difficult to justify for single-dose oncology use.

Is mannitol essential to carboplatin injection?

Mannitol is common but is not inherently the only viable excipient. A sponsor would need to demonstrate acceptable tonicity, stability, compatibility, sterility, and safety for any alternative system.

Can carboplatin be sold as a prefilled syringe?

A prefilled syringe is technically possible but requires extensive assessment of syringe materials, extractables, leachables, plunger compatibility, dose accuracy, hazardous-drug handling, and administration practice. The commercial value depends on whether it reduces preparation steps without creating dosing limitations.

Does carboplatin require a new patent for market differentiation?

A patent is not required to commercialize a generic carboplatin product. It is useful when the product depends on a defendable formulation, container, process, or integrated administration system that supports premium pricing or contract protection.

What is the most attractive carboplatin product concept?

A preservative-free, ready-to-use, aluminum-controlled infusion product with validated extended stability and standardized concentrations has the strongest balance of technical feasibility and commercial relevance.

References

1. U.S. Food and Drug Administration. (1989). Paraplatin approval history and labeling information. FDA.

2. DailyMed. (2024). Carboplatin injection, solution: Prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

5. U.S. Pharmacopeia. (2023). General chapter <797>: Pharmaceutical compounding - sterile preparations. United States Pharmacopeial Convention.